Merck Of Germany’s Garijo Highlights COVID-19 Vaccine Effective In Mavenclad-Treated MS
COVID-Related Solutions Drive Growth In Q1
Executive Summary
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.